Independent Director · Kiniksa Pharmaceuticals International, plc (KNSA)

G. Bradley Cole — Kiniksa Pharmaceuticals International Director Compensation (2025)

Fiscal year 2025 director compensation for G. Bradley Cole at Kiniksa Pharmaceuticals International, plc. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 16, 2026 (DEF 14A). Open the filing on EDGAR.

Free

Get G. Bradley Cole’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track G. Bradley Cole and every company like it: Velarion Intel, free for 3 days, no card →

What they were paid

Kiniksa Pharmaceuticals International Director Compensation Table · all 3 fiscal years held
In US dollars, as Kiniksa Pharmaceuticals International reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$59,999$81,479$255,162$0$396,640
FY2022$49,000$49,400$187,602—$286,002
FY2021$49,000—$297,936—$346,936

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kiniksa Pharmaceuticals International, plc DEF 14A filed April 16, 2026, accession 0001104659-26-044410, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kiniksa Pharmaceuticals International, plc filed document, accession 0001104659-26-044410. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.

Get the Kiniksa Pharmaceuticals International Board Governance Report

$396,640 G. Bradley Cole, FY2025 total director compensation

$500

The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.

Data as of April 16, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

How this board is paid

company policy · FY2025

Kiniksa Pharmaceuticals International pays directors a $50,000 cash retainer and $340,000 in RSUs/Options.

Committees

FY2025 · as the proxy prints them

Audit

The rest of the Kiniksa Pharmaceuticals International board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Barry D. QuartIndependent Director$414,640
Felix J. BakerLead Independent Director$430,640
Kimberly J. PopovitsIndependent Director$406,640
M. Cantey BoydIndependent Director$395,641
Richard S. LevyIndependent Director$466,630
Sanj K. PatelChair of the Board—
Stephen R. BiggarIndependent Director$405,640
Thomas R. MalleyIndependent Director$411,640
Tracey L. McCainIndependent Director$396,640

The full Kiniksa Pharmaceuticals International compensation record

free company brief

This page is one director within Kiniksa Pharmaceuticals International's record. The company brief lists every named executive and director, each linking to their own page.

Peer companies

named in the Kiniksa Pharmaceuticals International proxy · each links to its own free brief

Order KNSA

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Board Governance Report